- Home
- COOK vs ELDN Comparison
COOK vs ELDN Comparison
Compare COOK & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COOK
- ELDN
- Stock Information
- Founded
- COOK 1985
- ELDN 2004
- Country
- COOK United States
- ELDN United States
- Employees
- COOK N/A
- ELDN N/A
- Industry
- COOK Wholesale Distributors
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- COOK Consumer Discretionary
- ELDN Health Care
- Exchange
- COOK Nasdaq
- ELDN Nasdaq
- Market Cap
- COOK 209.0M
- ELDN 202.4M
- IPO Year
- COOK 2021
- ELDN N/A
- Fundamental
- Price
- COOK $1.41
- ELDN $2.72
- Analyst Decision
- COOK Buy
- ELDN Strong Buy
- Analyst Count
- COOK 7
- ELDN 2
- Target Price
- COOK $2.29
- ELDN $12.50
- AVG Volume (30 Days)
- COOK 272.6K
- ELDN 1.0M
- Earning Date
- COOK 08-06-2025
- ELDN 08-22-2025
- Dividend Yield
- COOK N/A
- ELDN N/A
- EPS Growth
- COOK N/A
- ELDN N/A
- EPS
- COOK N/A
- ELDN N/A
- Revenue
- COOK $579,453,000.00
- ELDN N/A
- Revenue This Year
- COOK $0.06
- ELDN N/A
- Revenue Next Year
- COOK $3.18
- ELDN N/A
- P/E Ratio
- COOK N/A
- ELDN N/A
- Revenue Growth
- COOK N/A
- ELDN N/A
- 52 Week Low
- COOK $1.28
- ELDN $2.38
- 52 Week High
- COOK $3.97
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- COOK 32.95
- ELDN 37.28
- Support Level
- COOK $1.52
- ELDN $2.41
- Resistance Level
- COOK $1.76
- ELDN $3.51
- Average True Range (ATR)
- COOK 0.10
- ELDN 0.28
- MACD
- COOK -0.05
- ELDN -0.10
- Stochastic Oscillator
- COOK 7.84
- ELDN 19.81
About COOK Traeger Inc.
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.